New hope for tough arthritis cases?

NCT ID NCT07412704

Not yet recruiting Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug, BMS-986528, in 84 adults with rheumatoid arthritis that hasn't responded well to other treatments. The main goal is to check safety and how the body processes the drug. Researchers will also look for signs that it might help control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHRITIS, RHEUMATOID

Contacts and locations

Locations

Local Institution - 0001

Shanghai, Shanghai Municipality, 200127, China
Local Institution - 0006

Beijing, Beijing Municipality, 100091, China
Local Institution - 0007

Nanchang, Jiangxi, 330006, China
Local Institution - 0010

Zhengzhou, Henan, 450000, China
Local Institution - 0017

Roma, 00168, Italy
Local Institution - 0019

Rozzano, Milano, 20089, Italy
Local Institution - 0020

Shanghai, Shanghai Municipality, 200040, China
Local Institution - 0021

Cologne, 50937, Germany
Local Institution - 0022

Berlin, 10117, Germany
Local Institution - 0023

Józefów, Masovian Voivodeship, 05-410, Poland
Local Institution - 0027

Geneva, 1211, Switzerland
Local Institution - 0028

Herne, 44652, Germany
Local Institution - 0033

Porto Alegre, Rio Grande do Sul, 90050-010, Brazil
Local Institution - 0037

Bern, 3010, Switzerland
Local Institution - 0039

A Coruña, A Coruña [La Coruña], 15006, Spain
Local Institution - 0040

München, Bavaria, 81377, Germany
Local Institution - 0045

Budapest, 1085, Hungary
Local Institution - 0048

Merksem, Flanders, 2170, Belgium
Local Institution - 0049

Leuven, 3000, Belgium
Local Institution - 0050

Aurora, Colorado, 80045, United States
Local Institution - 0051

DeSoto, Texas, 75115, United States
Local Institution - 0053

México, 14080, Mexico
Local Institution - 0055

South Miami, Florida, 33143, United States
Local Institution - 0056

Sendenhorst, 48324, Germany
Local Institution - 0057

San Antonio, Texas, 78229, United States
Local Institution - 0058

Córdoba, Córdoba, 14004, Spain
Local Institution - 0060

Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76008, Ukraine
Local Institution - 0061

Ternopil, 46002, Ukraine
Local Institution - 0062

Kyiv, 02000, Ukraine
Local Institution - 0063

Poltava, Poltava Oblast, 36011, Ukraine
Local Institution - 0064

Kyiv, Kyiv Oblast, 01135, Ukraine
Local Institution - 0065

Potsdam, 14467, Germany
Local Institution - 0066

Portland, Oregon, 97239, United States
Local Institution - 0067

Denver, Colorado, 80218, United States
Local Institution - 0068

La Jolla, California, 92037, United States
Local Institution - 0069

Palo Alto, California, 94304-2210, United States
Local Institution - 0070

Loma Linda, California, 92354, United States
Local Institution - 0071

Philadelphia, Pennsylvania, 19107, United States
Local Institution - 0079

New York, New York, 10029, United States
Local Institution - 0080

Guangzhou, Guangdong, 510260, China
Local Institution - 0081

New York, New York, 10016, United States
Local Institution - 0082

Valinhos, São Paulo, 13271-130, Brazil
Local Institution - 0083

Aparecida de Goiânia, Goiás, 74935-530, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.